瑞波西汀与氟西汀治疗卒中后抑郁对照研究

A comparative study of Reboxetine and Fluoxetine in the treatment of past-stroke depression

目的:观察瑞波西汀对卒中后抑郁及神经功能康复的影响。方法:62例卒中后抑郁(PSD)患者被随机分为瑞波西汀组(30例)和氟西汀组(32例)进行为期6周的治疗观察,以汉密尔顿抑郁量表(HAMD)和副反应量表(TESS)于治疗前及治疗后1、2、4、6周末分别评定抗抑郁疗效和不良反应,以爱丁堡-斯堪的那维亚卒中量表(MESSS)于治疗前和治疗结束时评定神经功能缺损程度。结果:治疗结束时两组HAMD、MESSS评分均较疗前呈非常显著性下降(P均<0.01),组间比较无显著性差异。但两组HAMD评分于治疗第2周末时有显著性差异,提示瑞波西汀较氟西汀起效早。治疗各周两组TESS评分比较均无显著性差异。结论:瑞波西汀在治疗PSD和促进PSD患者的神经功能康复方面具有起效快、疗效好、不良反应小、安全性高的优点。

Objective：To observe the effectiveness of Reboxetine on the depressive symptoms and nervous functional rehabilitation of the patients with past-stroke depression（PSD）.Methods：62 patients with PSD were assigned randomly into Reboxetine group（n=30） and Fluoxetine group（n=32） for a 6-weeks treatment.HAMD,MESSS and TESS scales evaluated the efficacy and side reactions respectively.Results： The clinical therapeutic efficacies in two groups were both significantly well and there was no significant difference between them.There was a significant difference in HAMD scores between the two groups in the second week after treatment,and it meant that Reboxetine had an earlier beginning time of efficacy.No significant differences were fund in TESS scores between two groups.Conclusions： Reboxetine can significantly improve the depressive symptoms and neurological functional rehabilitation,and it has quick effects and light side reactions.